GLP 1 Insurance Coverage

Saxenda, an FDA-approved weight-management medication (liraglutide), is covered by several major carriers with prior authorization similar to Wegovy's criteria, though it has generally been overtaken in formulary preference by newer, more effective medications like Wegovy and Zepbound.

Zepbound coverage for obesity varies by payer similarly to Wegovy, with a distinct, often stronger coverage pathway for its FDA-approved obstructive sleep apnea indication; Medicare Advantage plans began covering Zepbound for obesity in April 2026 at a capped copay under the Treat and Reduce Obesity Act.

Medicaid GLP-1 coverage is state-determined, not federally uniform, most states cover GLP-1 medications for type 2 diabetes, while coverage for obesity varies significantly by state, with some states covering it, others excluding it, and requirements like prior authorization differing across state Medicaid programs.

Cigna, through its Express Scripts pharmacy benefit manager, covers Ozempic, Mounjaro, Wegovy, and Zepbound for FDA-approved indications on most commercial formularies, with obesity coverage requiring prior authorization, sometimes step therapy through a medication like Contrave first, and ongoing weight-loss benchmarks to maintain coverage.

UnitedHealthcare, administered through OptumRx, covers Ozempic and Mounjaro for type 2 diabetes on virtually all commercial plans, and covers Wegovy/Zepbound for obesity on roughly 72% of commercial plans with prior authorization, having eliminated mandatory step therapy for most obesity PAs in 2025.

A GLP-1 insurance denial is common but not final. Well-documented appeals succeed roughly 30 to 40 percent of the time, and understanding the specific reason for denial is the most important step before appealing.

Medicare Part D has covered Ozempic and Mounjaro for type 2 diabetes for years. As of July 1, 2026, a new program called the Medicare GLP-1 Bridge covers Wegovy, Zepbound, and Foundayo for weight loss at a flat $50 monthly copay for eligible beneficiaries, the first time Medicare has covered a GLP-1 for weight loss alone.

Rybelsus, the oral form of semaglutide, is covered for type 2 diabetes on most commercial and Medicare plans with standard prior authorization, similar to Ozempic, though formulary placement and specific plan participation vary and are worth confirming directly.

Wegovy coverage for obesity varies significantly by payer and plan, roughly 50-72% of commercial plans cover it with prior authorization; a separate, often more reliable coverage pathway exists for its FDA-approved cardiovascular indication, and Medicare coverage for weight loss specifically opens through the new Bridge Program starting July 2026.

Standard Medicare Part D does not cover GLP-1 medications for weight loss alone, a longstanding rule, though it covers diabetes and, since 2024, cardiovascular and sleep apnea indications. The Medicare GLP-1 Bridge Program, launching July 1, 2026, opens a new $50/month copay pathway specifically for weight-loss coverage of Foundayo, Wegovy, and Zepbound, administered nationally through Humana as CMS's central processor.

Aetna group and commercial plans generally cover Wegovy and Zepbound for weight loss with prior authorization (BMI 30+, or 27+ with comorbidity), while individual marketplace plans often exclude GLP-1 medications entirely, sometimes covering alternatives like Contrave or Qsymia instead.

Many insurance plans, including many self-funded employer plans, explicitly exclude coverage for weight-loss medications while still covering the exact same drug when prescribed for diabetes, a real, common, and legal coverage distinction based on the stated reason for the prescription.

Prior authorization requires your doctor to document medical necessity before your insurer will cover a GLP-1 medication. Coverage odds differ significantly by indication, roughly 85 percent for diabetes-coded Ozempic versus roughly 45 percent for weight-loss-coded Wegovy.

Mounjaro is covered for type 2 diabetes on virtually every major commercial and Medicare plan with standard prior authorization; it is not FDA-approved for weight loss (Zepbound is the approved weight-management version of tirzepatide) and is generally not covered when prescribed for that purpose.

Ozempic is covered for type 2 diabetes on virtually every major commercial and Medicare plan, requiring prior authorization with documented HbA1c of 7.0% or higher and a prior metformin trial; Ozempic is not FDA-approved for weight loss and is generally denied when prescribed for that purpose specifically.

Humana covers Ozempic and Mounjaro for type 2 diabetes broadly, and as of April 2026 covers Wegovy and Zepbound for obesity on Medicare Advantage plans at a $50/month copay cap under the Treat and Reduce Obesity Act; CMS also selected Humana as the national central processor for the Medicare GLP-1 Bridge Program launching July 2026.

Blue Cross Blue Shield is not a single insurer but a federation of roughly 34 independent companies, each setting its own GLP-1 coverage policy; several major affiliates (Massachusetts, Vermont, Michigan, Harvard Pilgrim) excluded GLP-1 weight-loss coverage entirely starting January 1, 2026, while others continue covering it with prior authorization.

Manufacturers offer direct savings programs, NovoCare for Wegovy and Ozempic, LillyDirect for Zepbound and Mounjaro, that can significantly lower cash-pay costs, though government-plan beneficiaries are generally excluded from these programs.

Medicaid coverage for GLP-1 medications varies significantly by state, since each state runs its own program. Nearly all states cover Ozempic and Mounjaro for type 2 diabetes, but coverage for weight-loss-specific use of Wegovy and Zepbound is inconsistent and has actually declined in some states recently.